Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB) price closed lower on Friday, November 17, dropping -13.76% below its previous close.
A look at the daily price movement shows that the last close reads $0.66, with intraday deals fluctuated between $0.525 and $0.6399. The company’s 5Y monthly beta was ticking -0.13. Taking into account the 52-week price action we note that the stock hit a 52-week high of $5.35 and 52-week low of $0.50. The stock subtracted -32.24% on its value in the past month.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
Chemomab Therapeutics Ltd ADR, which has a market valuation of $7.06 million, is expected to release its quarterly earnings report Nov 09, 2023. Analysts tracking CMMB have forecast the quarterly EPS to shrink by -0.02 per share this quarter, while the same analysts predict the annual EPS to hit -$0.07 for the year 2023 and up to -$0.09 for 2024. In this case, analysts estimate an annual EPS growth of 41.70% for the year and -28.60% for the next year.
Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with no upward and no downward reviews. On the technical perspective front, indicators give CMMB a short term outlook of 100% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 2 analysts have assigned CMMB a recommendation rating as follows: 1 rate it as a Hold; 1 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the Chemomab Therapeutics Ltd ADR (CMMB) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Overweight, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
The overview shows that CMMB’s price is at present -21.21% off the SMA20 and -33.10% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 37.46, with weekly volatility standing at 28.60%. The indicator jumps to 17.63% when calculated based on the past 30 days. Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB)’s beta value is holding at 0.36, while the average true range (ATR) indicator is currently reading 0.12. Considering analysts have assigned the stock a price target range of $7.00-$7.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $7.00. Based on this estimate, we see that current price is roughly -1128.07% off the estimated low and -1128.07% off the forecast high. Investors will no doubt be excited to see the share price fall to $7.00, which is the median consensus price, and at that level CMMB would be -1128.07% from current price.
An analysis of the Chemomab Therapeutics Ltd ADR (NASDAQ:CMMB) stock in terms of its daily trading volume indicates that the 3-month average is 1.24 million. However, this figure increases on the past 10-day timeline to an average of 8.03 million.
Current records show that the company has 11.63M in outstanding shares. The insiders’ percentage holdings are 0.00% of outstanding shares while the percentage share held by institutions stands at 2.42%. The stats also highlight that short interest as of Oct 30, 2023, stood at 32159.999999999996 shares, which puts the short ratio at the time at 1.43. From this we can glean that short interest is 0.29% of company’s current outstanding shares. Notably, we see that shares short in October fall slightly given the previous month’s figure stood at 46030.0. But the -82.21% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
